An Elevated Gap between Admission and A1C-Derived Average Glucose Levels Is Associated with Adverse Outcomes in Diabetic Patients with Pyogenic Liver Abscess

Wen-I Liao¹, Wayne Huey-Herng Sheu², Wei-Chou Chang³, Chin-Wang Hsu⁴, Yu-Long Chen¹, Shih-Hung Tsai¹*

¹Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ²Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ³Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ⁴Department of Emergency and Critical Care Medicine, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan

Abstract

Objectives: To assess whether chronic glycemic control and stress-induced hyperglycemia, determined by the gap between admission glucose levels and A1C-derived average glucose (ADAG) levels adversely affects outcomes in diabetic patients with pyogenic liver abscess (PLA).

Methods: Clinical, laboratory, and multi-detector computed tomography (MDCT) findings of 329 PLA patients (2004–2010) were retrospectively reviewed. HbA1C levels were used to determine long-term glycemic control status, which were then converted to estimated average glucose values. For the gap between admission glucose levels and ADAG levels, we used receiver operating characteristic (ROC) curve to determine the optimal cut-off values predicting adverse outcomes. Univariate and multivariate logistic regressions were used to identify predictors of adverse outcomes.

Results: Diabetic PLA patients with poor glycemic control had significantly higher Klebsiella pneumoniae (KP) infection rates, lower albumin levels, and longer hospital stays than those with suboptimal and good glycemic control. The ROC curve showed that a glycemic gap of 72 mg/dL was the optimal cut-off value for predicting adverse outcomes and showed a 22.3% relative increase in adverse outcomes compared with a glycemic gap <72 mg/dL. Multivariate analysis revealed that an elevated glycemic gap ≥72 mg/dL was important predictor of adverse outcomes.

Conclusions: A glycemic gap ≥72 mg/dL, rather than admission hyperglycemia or chronic glycemic control, was significantly correlated with adverse outcomes in diabetic PLA patients. Poorer chronic glycemic control in diabetic PLA patients is associated with high incidence of KP infection, hypoalbuminemia and longer hospital stay.

Introduction

Stress-induced hyperglycemia commonly occurs in patients with critical illness including trauma, burn injuries, surgeries, myocardial infarction, and sepsis [1]. Acute hyperglycemia on admission can be caused by the presence of excessive counter-regulatory hormones (glucagon, growth hormone, catecholamines, and glucocticosid) and anti-inflammatory cytokines as well increased gluconeogenesis and hepatic insulin resistance. [1–3].

Elevated blood glucose levels may indicate a severe illness with an increased response to stress. However, paradox existed in the discordant findings in the correlation between hyperglycemia and adverse outcomes in acute-ill patients with or without preexisting diabetes. In nondiabetic patients with infections, admission hyperglycemia was associated with adverse outcomes with a J-shaped curve (i.e., patients with initial glucose levels <100 mg/dL and >200 mg/dL have worse outcomes compared with those normal glucose levels) [4]. Nonetheless, the association between admission hyperglycemia and acute illness in patients with diabetes remains to be controversial. [4–6]. Several studies argued against the association between admission hyperglycemia and adverse outcomes in infected diabetic patients [4,7]. In diabetic patient suffering acute illness, the epiphenomenon of acute hyperglycemia in patients with acute illnesses can result from acute physiological stress, chronic baseline blood glucose levels or both [7].
Glycated hemoglobin (HbA1c) reflects long-term glycemic control over the preceding 2–3 months; it is a better index of overall glycemic exposure and is characterized by lower biological variability, no fasting requirement, relative stability at room temperature, and is relatively unaffected by acute stress or sepsis [8]. An international multicenter A1C-derived average glucose (ADAG) study demonstrated a strong correlation between HbA1C and long-term mean plasma glucose levels in the preceding 3 months, which allows estimation of long-term average glucose levels using HbA1C values [9]. We speculated that elevated admission hyperglycemia in infected diabetic patients may reflect stress-induced hyperglycemia, a consequence of long-term poor glycemic control or in combination. This method allowed us to test the association between acute stress-induced hyperglycemia by eliminating the influence of chronic hyperglycemia on the admission hyperglycemia in patient with pre-existing diabetes.

We hypothesize that the gap between admission hyperglycemia and the estimated long-term average glucose levels (eAG) could represent stress-induced glycemic deterioration more properly than admission hyperglycemia alone among diabetic patients. This method may aid in investigating the sepsis severity in diabetic patients. To test this hypothesis, we conducted the present study on a well-known diabetic patient prone infection—pyogenic liver abscess (PLA) [10–13].

The purpose of this study was to clarify whether the gap between admission glucose levels and eAG derived from admission HbA1C levels could predict adverse outcomes in diabetic PLA patients. In addition, the relationship between long-term glycemic control and clinical outcomes in diabetic PLA patients were analyzed.

Materials and Methods

Patients

This retrospective study was conducted at a tertiary referral medical center in northern Taiwan and was approved by the institutional review board for human investigations. The requirement for written informed consent from the patients was waived because patient anonymity was strictly maintained and the study was observational. A search of the institutional database using the International Classification of Diseases (9th revision, code 572.0) identified 333 PLA patients diagnosed (January 2004 and March 2010) during hospitalization. PLA was diagnosed if at least 1 of the following criteria was met: (1) pus was drained by percutaneous catheter drainage (PCD); (2) bacterial pathogens were isolated from blood or abscess cultures; and (3) the intrahepatic cavity was resolved with antibiotics, surgery, or PCD. Patients with hemoglobin diseases (Hbs, HbC, HbF, and HbE) that could interfere with HbA1C assay, those with conditions influencing red cell turnover (i.e., hemolytic anemia, chronic malaria, or major blood loss), and those infected with pathogens originating from amebiasis were excluded.

Methods

Two authors retrospectively reviewed the medical records of PLA patients for age, gender, HbA1C levels, clinical presentation, underlying diseases, MDCT parameters, laboratory data at initial presentation, adverse outcomes, and hospital stay duration. The patients were initially divided into 2 groups (diabetic and nondiabetic). Diabetes was considered present if a patient had a hospital discharge diagnosis of type 1 or type 2 diabetes, and/or had an HbA1C level ≥6.5% in the preceding 2 months [8]. The diabetic patients were further divided into 3 subgroups on the basis of HbA1C levels as follows: HbA1C ≤7% indicating good chronic glycemic control, 7% < HbA1C < 9% indicating suboptimal chronic glycemic control, and HbA1C ≥9% indicating poor chronic glycemic control. The HbA1C cut-off value selection was based on previous studies [14–17]. The included patients were treated with antibiotics alone, antibiotics (most commonly ceftriaxone) plus PCD, or antibiotics plus surgery. The antibiotic was subsequently adjusted according to the blood or abscess culture results. Pus was aspirated by PCD and sent for microbiological analysis. The adverse outcomes included mortality; metastatic infection (defined as a distal infection with the same bacterium as the PLA culture); septic shock (defined and treated by the criteria of the Surviving Sepsis Campaign) [18]; acute hepatic failure (defined as the development of severe acute liver injury with coagulopathy and encephalopathy); acute respiratory failure (defined as patients requiring mechanical ventilation); upper gastrointestinal (UGI) bleeding (defined as endoscopic evidence of stress-related mucosal bleeding, bright red blood per nasogastric tube, or melena); acute renal failure (defined as an increase in serum creatinine > 0.5 mg/dL from baseline) during the hospital stay; acute myocardial infarction (an episode of acute myocardial infarction) during hospitalization, and empyema.

HbA1C and Glucose Measurements

HbA1C levels that were determined in patients within 1 week prior to their current visit or in the 1st week of admission were collected. HbA1C was analyzed at Tri-Service General Hospital (Taipei, Republic of China) using a blood analyzer (Primus CLC 385; Primus Corporation, Kansas City, MO, USA). This assay used a high-performance liquid chromatography system, standardized to the Diabetes Control and Complication Trial. The laboratory received National Glycohemoglobin Standardization Program Level 1 certification for this method.

The admission glucose level was defined as the plasma glucose level measured at the initial presentation. Hyperglycemia was defined as admission glucose level ≥200 mg/dL, which was used by several previous hyperglycemia studies [2,3,19]. The eAG over the previous 3 months was calculated by the equation: AG = 28.7 × HbA1C − 46.7 [9]. The glycemic gap was defined as admission glucose levels obtained at initial presentation minus eAG.

Statistical Analysis

Continuous data were expressed as means ± standard deviations and analyzed using the two-tailed Student’s t-test. Categorical data were expressed as frequencies (%) and tested using the chi-squared or Fisher’s exact test. One-way analysis of variance was used to examine the significance levels for various characteristics, laboratory data, and clinical outcomes in HbA1C-categorized groups. Hypoglycemic (blood glucose level < 70 mg/dL) diabetic patients were excluded while analyzing the glycemic gap. A receiver operator characteristic (ROC) curve was plotted to classify adverse outcomes in diabetic PLA patients on the basis of the glycemic gap. Univariate logistic regression analysis was used to determine possible predictors associated with adverse outcomes. We selected all parameters for which the P-value was < .05 in the initial univariate results and gender, age, and gas formation for multivariate analyses to determine the predictors most strongly associated with adverse outcomes. The data were analyzed using the Statistical Package for the Social Sciences version 17.0 statistical software (SPSS, Inc., Chicago, IL, USA), and differences with P-values < .05 were considered statistically significant.
Results

The Demographic Data and Underlying Disease

A total of 333 PLA patients were enrolled, but 3 were excluded because of amebic liver abscesses and 1 patient was excluded because of PCD-associated hemorrhagic shock. There were 165 (50.2%) patients with diabetes and 164 (49.8%) patients without diabetes. Among the diabetic patients, 135 (81.8%) had recorded HbA1C levels. Based on the HbA1C levels of the diabetic patients, 33 patients (24.4%) had good glycemic control, 39 (28.9%) had suboptimal glycemic control, and 63 (46.7%) had poor glycemic control. The diabetic patients were older (P = .002), had lower incidences of cancer (P = .01) and chronic hepatic B (P = .02), and 12.4% lower chance of initially presenting with right upper quadrant (RUQ) abdominal pain (P = .02) than the nondiabetic patients (Table 1). The diabetic patients with poor glycemic control were younger than those with suboptimal and good glycemic control (P = .02).

Laboratory Data and MDCT Parameters

*Klebsiella pneumoniae* (KP) was the most common organism isolated (68.7%) from both blood and abscess cultures of PLA patients. KP infections were more frequently observed in diabetic patients (74.5%) than in nondiabetic patients (62.8%, P = .02). In addition, the poor glycemic control group had a significantly higher KP infection rate (89.1%) than the suboptimal (71.8%) and good (63.6%) glycemic control groups (P = .03) (Table 2). Triglyceride levels were significantly higher and the sodium levels were significantly lower in the diabetic patients compared with the nondiabetic patients, but there were no significant differences among the glycemic control groups. The albumin levels were significantly lower in the diabetic patients than in nondiabetic patients, but there were no significant differences in the glycemic gap analysis. Among the diabetic group (8.5%) had a higher mortality rate than the diabetic group (4.2%), without statistically significant differences (Table 3). The most common clinical adverse outcomes were acute respiratory failure (14.0%) and septic shock (13.1%). Only acute hepatic failure was significantly higher in nondiabetic (6.1%) patients than diabetic patients (0.6%, P = .006).

The Gap between Admission Glucose Level and eAG

Three of 165 diabetic PLA patients had no recorded admission glucose levels, and 1 patient with an admission glucose level of 50 mg/dL was excluded from the glycemic gap analysis. The ROC curve revealed that a glycemic gap of 72 mg/dL was the optimal cut-off value for predicting adverse outcomes in diabetic PLA patients. The area under the ROC curve was 0.631 with a sensitivity of 59.5% and specificity of 68.1% (Figure 1).

Compared with diabetic PLA patients with a glycemic gap $\leq$ 72 mg/dL (19.2%), those with glycemic gaps $\geq$ 72 mg/dL

### Table 1. The comparison of the characteristic and underlying disease between non-diabetes mellitus (non-DM) and diabetic mellitus (DM) patients with pyogenic liver abscess.

| Characteristic | Non-DM (n = 164) | DM (n = 165) | p value | HbA1C ≤ 7% (n = 33) | 7%<HbA1C<9% (n = 39) | HbA1C ≥ 9% (n = 63) | p value |
|---------------|-----------------|-------------|---------|---------------------|------------------|------------------|---------|
| Age (years)   | 58.6±17.2       | 64.2±14.0   | .002    | 66.8±14.5           | 66.6±13.0        | 60.1±14.0        | .02     |
| Body-mass index | 24.1±4.1     | 25.1±3.7    | .12     | 25.1±3.7            | 25.5±4.1         | 33.5±51.3        | .59     |
| Male          | 102(62.2)       | 90(54.5)    | .20     | 16(48.5)            | 18(46.2)         | 41(64.1)         | .14     |
| Underlying    |                 |             |         |                     |                  |                  |         |
| disease       |                 |             |         |                     |                  |                  |         |
| Biliary tract disease | 38(23.2) | 40(24.2) | .82 | 6(18.2) | 11(28.2) | 13(20.3) | .53 |
| Cancer        | 37(22.6)        | 20(12.1)    | .01     | 3(9.1)              | 5(12.8)          | 8(12.5)          | .86     |
| CHF           | 1(0.6)          | 6(3.6)      | .06     | 1(3.0)              | 1(2.6)           | 3(4.7)           | .84     |
| Chronic hepatitis B | 18(11.0) | 7(4.2) | .02 | 1(3.0) | 1(2.6) | 2(3.1) | .98 |
| Chronic hepatitis C | 4(2.4) | 10(6.1) | .17 | 1(3.0) | 0(0) | 0(0) | .21 |
| Liver cirrhosis | 10(6.1) | 6(3.6) | .29 | 1(3.0) | 2(5.1) | 0(0) | .21 |
| Alcoholism    | 12(7.3)         | 6(3.6)      | .21     | 1(3.0)              | 2(5.1)           | 2(3.1)           | .48     |
| Remia         | 7(4.3)          | 11(6.7)     | .34     | 1(3.0)              | 4(10.3)          | 3(4.7)           | .37     |
| CVA           | 9(5.5)          | 16(9.7)     | .15     | 3(9.1)              | 4(10.3)          | 3(4.7)           | .52     |
| Initial presentation |      |             |         |                     |                  |                  |         |
| RUQ pain      | 74(45.1)        | 54(32.7)    | .02     | 7(21.2)             | 17(43.6)         | 19(29.7)         | .36     |
| Fever         | 151(92.1)       | 146(88.5)   | .27     | 29(87.9)            | 36(92.3)         | 54(84.4)         | .50     |

Values are expressed as mean± SD or number (%); CHF, congestic heart failure; CVA, cerebrovascular accident with bed ridden; RUQ, right upper quadrant.
Table 2. The comparison of the laboratory data and MDCT parameters between non-diabetes mellitus (non-DM) and diabetic mellitus (DM) patients with pyogenic liver abscess.

|                         | Non-DM (n = 164) | DM (n = 165) | p value | HbA1C £ 7% (n = 33) | 7%<HbA1C<9% (n = 39) | HbA1C ≥ 9% (n = 63) | p value |
|-------------------------|------------------|--------------|---------|---------------------|----------------------|---------------------|---------|
| WBC (µL)                | 14090±6589       | 14585±6112   | .48     | 14137±4724          | 14961±6471           | 14070±5922          | .73     |
| KP infection            | 103(62.8)        | 123(74.5)    | .02     | 21(63.6)            | 28(71.8)             | 57(89.1)            | .03     |
| Hemoglobin (g/dL)       | 12.04±2.16       | 11.92±2.00   | .61     | 12.08±1.99          | 11.68±2.17           | 12.25±1.93          | .39     |
| CRP (mg/dl)             | 21.2±10.0        | 20.8±10.5    | .68     | 17.5±9.1            | 22.2±10.8            | 21.8±10.6           | .10     |
| Na(mmol/L)              | 134.1±10.8       | 131.8±7.1    | .03     | 133.5±5.9           | 132.0±3.9            | 130.5±9.4           | .18     |
| Creatinine (mg/dl)      | 2.08±8.74        | 1.28±1.19    | .25     | 1.04±0.82           | 1.27±1.08            | 1.25±0.96           | .53     |
| Albumin (g/dl)          | 3.22±2.75        | 2.80±0.79    | .07     | 3.20±0.50           | 2.96±0.46            | 2.57±0.88           | <.001   |
| Triglyceride (mg/dl)    | 118±66           | 149±100      | .004    | 121±79              | 139±91               | 171±120             | .10     |
| Alk-PiU (µ/L)           | 185±158          | 165±127      | .26     | 169±163             | 144±92               | 165±113             | .67     |
| AST (U/L)               | 113±212          | 93±143       | .32     | 96±154              | 66±52                | 96±139              | .45     |
| Glucose (mg/dl)         | 125±37           | 275±152      | <.001   | 164±73              | 255±91               | 330±132             | <.001   |
| Size (cm)               | 6.1±2.9          | 6.1±2.6      | .85     | 6.0±2.6             | 5.8±2.5              | 6.4±2.7             | .44     |
| Gas formation           | 19(11.6)         | 28(17.0)     | .14     | 1(3.0)              | 8(20.5)              | 14(21.9)            | .17     |
| Cystic                  | 115(70.1)        | 113(68.5)    | .09     | 26(78.6)            | 25(64.1)             | 45(70.3)            | .39     |
| Septum                  | 92(56.1)         | 109(66.1)    | .10     | 24(72.7)            | 26(66.7)             | 40(62.5)            | .59     |
| Margin, well defined    | 100(61.0)        | 82(49.7)     | .004    | 20(60.6)            | 20(51.3)             | 30(46.9)            | .51     |
| Multiple                | 41(25.0)         | 29(17.6)     | .02     | 5(15.2)             | 8(20.5)              | 11(17.2)            | .89     |

Values are expressed as mean± SD or number (%); KP, Klebsiella Pneumonia; WBC, white blood cell count; CRP, C-reactive protein; T.bil, total bilirubin; Alk-P, Alkaline Phosphatase; AST, aspartate Transaminase.
doi:10.1371/journal.pone.0064476.t002

Table 3. The comparison of the treatment and clinical outcome between non-diabetes mellitus (non-DM) and diabetic mellitus (DM) patients with pyogenic liver abscess.

|                         | Non-DM (n = 164) | DM (n = 165) | p value | HbA1C £ 7% (n = 33) | 7%<HbA1C<9% (n = 39) | HbA1C ≥ 9% (n = 63) | p value |
|-------------------------|------------------|--------------|---------|---------------------|----------------------|---------------------|---------|
| Percutaneous drainage   | 122(74.4)        | 127(77.0)    | .49     | 29(87.9)            | 29(74.4)             | 51(79.7)            | .39     |
| Operation               | 23(14.0)         | 21(12.7)     | .57     | 3(9.1)              | 3(7.7)               | 9(14.1)             | .46     |
| Vasopressor required in the ED | 16(9.8)   | 11(6.7)      | .41     | 1(3.0)              | 4(10.3)              | 2(3.1)              | .06     |
| Hospital stay (days)    | 22.5±14.1        | 27.0±26.2    | .06     | 20.5±10.7           | 23.4±10.0            | 34.1±37.5           | .03     |
| Adverse outcomes        | 70(42.7)         | 67(40.6)     | .70     | 11(33.3)            | 16(41.0)             | 23(35.9)            | .78     |
| Mortality               | 14(8.5)          | 7(4.2)       | .17     | 0(0)                | 0(0)                 | 2(3.1)              | .31     |
| Metastatic infection    | 116(6.7)         | 14(8.5)      | .54     | 2(6.1)              | 2(6.1)               | 3(4.7)              | .53     |
| Acute renal failure     | 18(11.0)         | 11(6.7)      | .16     | 2(6.1)              | 1(2.6)               | 5(7.8)              | .54     |
| Acute respiratory failure| 19(11.6)      | 27(16.4)     | .21     | 2(6.1)              | 5(12.8)              | 11(17.2)            | .30     |
| Acute hepatic failure   | 10(6.1)          | 1(0.6)       | .006    | 0(0)                | 0(0)                 | 0(0)                | -       |
| Empyema                 | 3(1.8)           | 3(1.8)       | .99     | 0(0)                | 1(2.6)               | 1(1.6)              | .66     |
| UGI bleeding            | 14(8.5)          | 11(6.7)      | .52     | 2(6.1)              | 4(10.3)              | 3(4.7)              | .53     |
| Multi-organ failure     | 10(6.1)          | 8(4.8)       | .61     | 0(0)                | 0(0)                 | 3(4.7)              | .17     |
| Acute myocardial infarction| 3(1.8)   | 8(4.8)       | .18     | 1(3.0)              | 2(5.1)               | 3(4.7)              | .85     |
| Septic shock            | 21(12.8)         | 22(13.3)     | .88     | 1(3.0)              | 3(7.7)               | 9(14.1)             | .19     |

Values are expressed as mean± SD or number (%); UGI bleeding, upper gastrointestinal bleeding.
doi:10.1371/journal.pone.0064476.t003
had a 22.3% relative increase in the incidence of adverse outcomes ($P=.005$), such as higher incidences of metastatic infections, acute respiratory failure, septic shock, empyema, and UGI bleeding. These outcomes did not show statistically significant differences, except for UGI bleeding ($P=.002$) (Table 4).

### Adverse outcomes vs. non-adverse outcomes

![ROC curve]

**Figure 1.** ROC analysis of glycemic gaps to adverse outcomes among diabetic PLA patients. ADAG; A1C-derived average glucose AUC; Area under the curve PLA; Pyogenic liver abscess ROC; Receiver operating characteristic.

doi:10.1371/journal.pone.0064476.g001

#### Univariate and Multivariate Logistic Regression Analysis

Univariate analysis showed that surgery, glycemic gaps $\geq 72$ mg/dL, anemia, creatinine levels $>1.3$ mg/dL, albumin levels $<3.5$ g/dL, total bilirubin levels $>1.2$ mg/dL, and alkaline phosphatase levels $>129$ mg/dL were correlated with adverse outcomes ($P<.05$), but admission glucose levels $>200$ mg/dL

#### Table 4. Clinical outcome versus Glucose- $A_1C$ derived average glucose (ADAG) in diabetic patients with pyogenic liver abscess.

|                      | Glucose-ADAG $<72$ mg/dL (n = 78) | Glucose-ADAG $\geq 72$ mg/dL (n = 53) | $p$ value |
|----------------------|----------------------------------|-------------------------------------|-----------|
| Adverse outcomes     | 15(19.2)                         | 22(41.5)                            | .005      |
| Metastatic infection | 4(5.1)                           | 6(11.3)                             | .19       |
| Acute renal failure  | 5(6.4)                           | 3(5.7)                              | .86       |
| Acute respiratory failure | 8(10.3)                     | 10(18.9)                            | .16       |
| Septic shock         | 7(9.0)                           | 8(15.1)                             | .28       |
| Empyema              | 0(0)                             | 2(3.8)                              | .08       |
| UGI bleeding         | 1(1.3)                           | 8(15.1)                             | .002      |
| Acute myocardial infarction | 4(5.1)                        | 2(3.8)                              | .54       |
| Multi-organ failure  | 2(2.6)                           | 1(1.9)                              | .79       |
| Mortality            | 2(2.6)                           | 1(1.9)                              | .68       |
| Hospital stay (days) | 24.3±17.5                        | 33.0±37.6                           | .06       |
| Percutaneous drainage| 65(83.3)                         | 40(75.5)                            | .26       |
| Operation            | 9(11.5)                          | 6(11.3)                             | .96       |

Values are expressed as mean± SD or number (%); UGI bleeding, upper gastrointestinal bleeding.

doi:10.1371/journal.pone.0064476.t004
were not (Table 5). Multivariate analysis showed that only a glycemic gap $\geq$72 mg/dL was a significant predictor of adverse outcomes in diabetic PLA patients.

### Discussion

In present study we have found that: 1) the glycemic gap rather than hyperglycemia on admission was a major predictor of adverse outcomes in diabetic PLA patients; 2) no correlation was observed between chronic glycemic control and adverse outcomes in diabetic PLA patients; and 3) poorer chronic glycemic control were associated with higher incidences of KP infection, hypoalbuminemia, and longer hospital stays in diabetic PLA patients.

Acute hyperglycemia has been linked to increased adverse outcomes in patients with trauma; [19] poorer neurological improvement and symptomatic hemorrhage in r-tPA treated patients with acute ischemic stroke; [20] severity of injury in patients with head trauma; [21] increased risk of in-hospital complications in patients with community-acquired pneumonia; [7,22] and major adverse cardiac events in patients with acute myocardial infarction [23]. Admission hyperglycemia has been linked with poorer outcomes in patients not known to have diabetes [24]. Nonetheless, admission hyperglycemia in the acute care setting has not consistently been shown to portend a worse prognosis in patients with preexisting diabetes. Furthermore, a recent study revealed that hyperglycemia was strongly associated with increased stays in intensive care units and mortality in critical non-diabetic patients, but not in diabetic patients [6]. Because hyperglycemia is a pronounced feature of diabetes, it is necessarily to consider pre-existing hyperglycemia in diabetic patients when investigating the association between sepsis-induced stress hyperglycemia and adverse outcomes. Our study was the first to investigate whether the glycemic gap was associated with adverse outcomes in diabetic PLA patients. In agreement with other study regarding infectious diseases, [4] we have shown that hyperglycemia on admission could not predict adverse outcomes in diabetic PLA patients. By using the concept of glycemic gap, we were able to eliminate the possible influence of chronic hyperglycemia on acute hyperglycemia by an HbA1c based eAG method. We subsequently found that acute surge of glucose levels beyond the long-term average glucose levels should be regard as a marker for the severity of sepsis in infected diabetic patients, in consistent with the admission hyperglycemia correlates with adverse outcomes in patient without pre-existing diabetes. We observed that elevated glycemic gaps $>72$ mg/dL can predict adverse outcomes in diabetic PLA patients rather than admission hyperglycemia alone. We hypothesize that the glycemic gap represented the true stress-induced hyperglycemia in infected diabetic patients. An increased stress response may reflect increased severity and consequent higher incidences of adverse outcomes. Egi et al demonstrated that pre-existing glycemic control may alter the association between acute hyperglycemia and mortality in diabetic patients with critical illnesses [25]. We thought that the concept of glycemic gap provide a new insight into the paradox of discordant results regarding the correlation between hyperglycemia and adverse outcomes in acute-ill patients with or without preexisting diabetes.

We used HbA1c levels to categorize a patient’s chronic glycemic control status and found that diabetic PLA patients with poor glycemic control had higher incidences of KP infection, longer hospital stays, hypoalbuminemia, compared with those with suboptimal and good glycemic control. Nevertheless, poorer chronic glycemic control was not associated with adverse outcomes or mortality in the present study. Several studies have demonstrated that KP-PLA frequently occurs in diabetic patients [26]. Poor chronic glycemic control can affect cell-mediated and humoral immune responses, resulting in infection [27]. Diabetic patients are susceptible to KP infections due to neutrophil phagocytosis of K1 and K2 capsular serotypes are impaired by poor glycemic control [28]. KP is the most commonly isolated microorganism in Asian PLA patients and accounts for most septic metastatic infections [11,29]. Our results further demonstrate that poorer glycemic control were associate with increased incidence of KP-PLA in diabetic patients.

Poor chronic glycemic control has been associated with significantly longer hospital stays for diabetic patients undergoing total joint arthroplasty; [30] increased risk of hospitalization for heart failure with type 2 diabetes; [31] unfavorable neurological and functional outcome of acute ischemic stroke; [32] increased risk of pneumonia related hospitalization; [33] a greater incidence of adverse outcomes and longer hospital stay after cardiac surgery in diabetic patients; [34] and higher risk of major amputation in critical limb ischemia patient undergoing percutaneous transluminal angioplasty [35]. Our study disclosed that diabetic PLA patients with poor chronic glycemic control had longer hospital stays than those with suboptimal and good glycemic control. We speculate that prolonged hospital stays may result from treatments for acute complications such as septic shock, acute respiratory failure, and difficult glucose control during hospitalization. Our results are in consistent with previous studies regarding PLA in diabetic patients had lower rates of cancer and RUQ pain during their initial presentations, compared to nondiabetic patients [36]. Although studies regarding distinctive CT features of PLA between diabetic and nondiabetic patients were limited, previous studies found that ill-defined margins and solitary abscess were more common in KP PLA [37,38]. Because KP is more commonly as the pathogen in diabetic PLA patients, it is reasonable that diabetic PLA patients have higher incidences of ill-defined solitary abscess. Hypoalbuminemia may reflect the incidences of diabetic nephropathy-related proteinuria and sup-

| Table 5. Univariate and multivariate logistic regression for risk factors associated with adverse outcomes. |
|---|---|---|
| Variable | Univariate analysis | Multivariate analysis |
| | Odd ratio(95%CI) | Odd ratio(95%CI) |
| Glucose-ADAG $\geq$ 72 mg/dL | 3.0(1.4–6.5)* | 6.9(1.8–26.3)* |
| Operation | 4.5(1.7–11.7)* | 2.4 (0.4–13.0) |
| Age $\geq$ 65 years | 1.04(0.5–2.0) | 1.0(0.3–3.5) |
| Male | 0.7(0.4–1.4) | 0.9(0.3–3.0) |
| Anemia* | 2.0(1.01–4.1)* | 0.8(0.2–2.8) |
| Creatinine $>$ 1.3 mg/ dl | 2.4(1.2–5.1)* | 2.3(0.5–9.6) |
| Albumin $<$ 3.5 g/dL | 7.0 (1.6–31.1)* | 2.2(0.2–21.5) |
| T.bil $>$ 1.2 mg/dL | 2.3(1.1–4.6)* | 2.3(0.7–7.8) |
| Alk-P $>$ 129 mg/dL | 2.2(1.02–4.7)* | 1.6(0.5–5.5) |
| Gas formation | 1.7(0.7–3.9) | 0.6(0.1–3.0) |
| Glucose $>$ 200 mg/dL | 2.2(0.4–9.7) | – |

ADAG, A1C derived average glucose; *Hemoglobin $<$ 13 g/dL in men, $<$ 12 g/dL in women; T.bil, total bilirubin; Alk-P, alkaline phosphatase; CI, confidence interval. 

*p $<$ 0.05.

Multivariate analysis: included all variable with P values $<$ 0.05 in the univariate analysis, age $\geq$ 65 years, male and gas formation.

doi:10.1371/journal.pone.0064476.t005
pressed albumin synthesis due to acute illnesses [39]. The diabetic PLA patients had higher triglyceride levels than non-diabetic PLA patients, probably because diabetes dysregulates lipoprotein metabolism accompanied by insulin resistance [40]. The higher incidence of acute hepatic failure in non-diabetic patients compared with diabetic patients may result from the higher comorbidity of cancers in non-diabetic patients than diabetic patients, especially hepatocellular carcinoma that accounted for approximately half (43.2%) of all cancers in non-diabetic patients.

An unexpected finding in this study was that diabetic PLA patients with glycemic gaps ≥72 mg/dL had higher incidences of UGI bleeding than those with gaps <72 mg/dL during hospitalization. A critical illness can result in stress-induced ulcers resulting from complex pathophysiological mechanisms, including decreased gastric mucosal blood flow, increased gastric mucosal permeability with increased acid back-diffusion, and ischemia-reperfusion injuries [41]. Acute Physiology and Chronic Health Evaluation (APACHE) II scores were independent predictors of acute gastrointestinal bleeding, i.e., the incidence of gastrointestinal bleeding was 1.45 times higher for every 10 point increase in the APACHE II score in patients with acute renal failure [42]. A positive correlation between plasma cortisol levels on admission and stress-induced ulcers have been demonstrated in patients with acute severe head injuries [43]. We speculate that the association between elevated glycemic gaps and UGI bleeding might have reflected greater severity of illness and physiological stress that promoted to the development of stress-induced ulcers with bleeding. However, further research is needed to discern whether a glycemic gap can predict the need of prophylaxis for stress-induced ulcers in diabetic PLA patients and in other settings.

Our study had several limitations. First, it was retrospective and selection bias could be existed. Second, we did not specifically address the treatments for hyperglycemia and glycemic controls during hospitalization although the adequacy of glycemic control during hospitalization may have influenced the outcomes [24]. Third, there were 30 (18.2%) diabetic patients without recorded HbA1C levels, including 5 patients who died. Our results may not be generalized to all diabetic PLA patients. Hence, further prospective and controlled studies are needed.

Conclusion

This study demonstrated that an elevated glycemic gap, rather than admission hyperglycemia or chronic glycemic control, was correlated with adverse outcomes in diabetic PLA patients. Poorer glycemic control in diabetic PLA patients resulted in higher incidences of KP-PLA and longer hospital stays. The concept of glycemic gap warrants further large-scale prospective studies in other acute illness in patients with diabetes.

Author Contributions

Conceived and designed the experiments: WII, WHHS YLC SHT. Performed the experiments: WCC CWH. Analyzed the data: WII YLC SHT. Contributed reagents/materials/analysis tools: WII, WHHS YLC SHT. Wrote the paper: WII WHHS SHT.

References

1. Marik PE, RagHAVAN M (2004) Stress hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30: 740–756.
2. McCowen KC, MalHotra A, Bistrian BR (2001) Stress-induced hyperglycemia. Crit Care Clin 17: 107–124.
3. Leontides L, Mouzaki A, Michalaki M, DeLuca-L: Kyriazopoulos V, et al. (2007) Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect 55: 340–346.
4. Schuetz P, Kennedy M, Lucas JM, Howell WC, Aird WC, et al. (2012) Initial management of septic patients with hyperglycemia in the noncritical care inpatient setting. Am J Med 125: 670–676.
5. Tiruvoipati R, Cheeze B, Lewis D, Orug K, Villanueva E, et al. (2012) Stress hyperglycemia may not be harmful in critically ill patients with sepsis. J Crit Care 27: 153–158.
6. Egi M, Belloomo R, Stachowski E, French CJ, Hart GK, et al. (2008) Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 36: 2249–2255.
7. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, et al. (2005) The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 28: 810–815.
8. (2009) International Expert Committee report on the role of the A1C assay in clinical care for diabetic patients in an orthopedic hospital in Kuwait. Med Princ Pract 18: 447–452.
9. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, et al. (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31: 1473–1478.
10. Lin JC, Siu LK, Fung CP, Tsou HH, Wang JJ, et al. (2006) Impaired host defenses and delayed phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control. J Microbiol Immunol Infect 37: 176–184.
11. Gallacher SJ, Thomson G, Fraser WD, Fisher BM, Gemmell CG, et al. (1995) Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med 12: 916–920.
12. Lin JC, Siu LK, Fung CP, Tsou HH, Wang JJ, et al. (2006) Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control. J Clin Endocrinol Metab 91: 3004–3007.
13. Thomsen RW, Jepsen P, Sorensen HT (2007) Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis 44: 1194–1201.
14. Wang GC, You CH, Ho MW, Wang JH (2004) Comparison of pyogenic liver abscess caused by non-Klebsiella pneumoniae and Klebsiella pneumoniae. J Microbiol Immunol Infect 37: 176–184.
15. Margolis DR, Hiatt JR, Vinson D Jr, Shabot MM (1994) Relationship of hyperglycemia and severity of illness to neurologic outcome in head injury patients. Ann Surg 160: 370–379.
16. Egi M, Belloomo R, Stachowski E, French CJ, Hart GK, et al. (2011) The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty. J Bone Joint Surg Am 91: 1621–1629.
17. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, et al. (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 36: 296–327.
18. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, et al. (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med 36: 296–327.
19. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy K, et al. (2005) Admission hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 59: 80–83.
20. Egi M, Belloomo R, Frankel MR, Brot TG, Lin Y, et al. (2002) Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59: 669–674.
21. Thomsen RW, Jepsen P, Sorensen HT (2007) Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis 44: 1194–1201.
22. Rueda AM, Ormond M, Gore M, Matthobi M, Giordano TP, et al. (2010) Hyperglycemia in diabetes and non-diabetes: effect on the risk for and severity of pneumococcal pneumonia. J Infect 60: 103–109.
23. Oswald GA, Smith CC, Bettezige DJ, Yudkin JS (1986) Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed) 293: 917–922.
24. Sackett DL, Haynes RB, Guyatt GH, Tugwell P (1997) Evidence Based Medicine: How to Practice and Teach. London: Churchill Livingstone, 2000.
25. Agarwal A, Pandey RK, Singh R, et al. (2012) Increased frequency of diabetic foot ulcers in patients with hypertension. J Family Med Prim Care 1: 128–131.
26. Yang CC, Yen CH, Ho MW, Wang JH (2004) Comparison of pyogenic liver abscess caused by non-Klebsiella pneumoniae and Klebsiella pneumoniae. J Microbiol Immunol Infect 37: 176–184.
27. Gallacher SJ, Thomson G, Fraser WD, Fisher BM, Gemmell CG, et al. (1995) Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med 12: 916–920.
28. Lin JC, Siu LK, Fung CP, Tsou HH, Wang JJ, et al. (2006) Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control. J Clin Endocrinol Metab 91: 3004–3007.
29. Fung CP, Chang FY, Lee SC, Hu BS, Kuo B, et al. (2002) A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important pathogen? Gut 50: 420–424.
30. Marchant MH Jr, Viens NA, Cook C, Vail TP, Bolognese MP (2009) The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty. J Bone Joint Surg Am 91: 1621–1629.
31. Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, et al. (2012) The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 55: 2946–2953.
32. Kamouchi M, Matsuki T, Hata J, Kurashiro T, Aga T, et al. (2011) Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry. Stroke 42: 2788–2794.
33. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, et al. (2008) Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31: 1541–1545.
34. Sato H, Carvalho G, Sato T, Lattermann R, Matsukawa T, et al. (2010) The association of preoperative glycemic control, intraoperative insulin sensitivity, and outcomes after cardiac surgery. J Clin Endocrinol Metab 95: 4338–4344.
35. Takahara M, Kaneto H, Iida O, Gorovaja S, Katakami N, et al. (2010) The influence of glycemic control on the prognosis of Japanese patients undergoing percutaneous transluminal angioplasty for critical limb ischemia. Diabetes Care 33: 2538–2542.
36. Foo NP, Chen KT, Lin HJ, Guo HR (2010) Characteristics of pyogenic liver abscess patients with and without diabetes mellitus. Am J Gastroenterol 105: 328–335.
37. Kim SB, Je BK, Lee KY, Lee SH, Chung HH, et al. (2007) Computed tomographic differences of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-Klebsiella pneumoniae. J Comput Assist Tomogr 31: 59–65.
38. Alsaif HS, Venkatesh SK, Chan DS, Archuleta S (2011) CT appearance of pyogenic liver abscesses caused by Klebsiella pneumoniae. Radiology 260: 129–130.
39. Don BR, Kayen G (2004) Serum albumin: relationship to inflammation and nutrition. Semin Dial 17: 432–437.
40. Annuzzi G, De Natale C, Iovine C, Patti L, Di Marino L, et al. (2004) Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 24: 2397–2402.
41. Laine L, Takeuchi K, Tarnawski A (2008) Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 135: 41–60.
42. Fiaccadori E, Maggiore U, Clima B, Mella L, Rotelli C, et al. (2001) Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int 59: 1510–1519.
43. Li ZM, Wang LX, Jiang LG, Zhu JX, Geng FY, et al. (2010) Relationship between plasma cortisol levels and stress ulcer following acute and severe head injury. Med Princ Pract 19: 17–21.